485 results about "Screening test" patented technology

The present invention is a cardiac rhythm-monitoring device, which allows patients to perform a preliminary screening for supraventricular arrhythmia. The device detects beat-to-beat heart rhythms (i.e. the R-R interval between individual heart beats) and performs a screening test to determine if there are indications of arrhythmia. The test looks for variance in the R-R interval that is outside of the normal range, either using a pre-constructed chart based upon general population studies to determine the normal range of variance or using normal distribution analysis of the patient's own heart rhythm to determine the normal range of variance for determining irregular heartbeats, and if there are multiple irregularities within the sensed time frame, the patient is warned of potential supraventricular arrhythmia. By sensing both electrical impulses form the heart and mechanical responses to the heartbeat, the device may augment its analysis.

The present invention is a cardiac rhythm-monitoring device, which allows patients to perform a preliminary screening for supraventricular arrhythmia. The device detects beat-to-beat heart rhythms (i.e. the R-R interval between individual heart beats) and performs a screening test to determine if there are indications of arrhythmia. The test looks for variance in the R-R interval that is outside of the normal range, either using a pre-constructed chart based upon general population studies to determine the normal range of variance or using normal distribution analysis of the patient's own heart rhythm to determine the normal range of variance for determining irregular heartbeats, and if there are multiple irregularities within the sensed time frame, the patient is warned of potential supraventricular arrhythmia. By sensing both electrical impulses form the heart and mechanical responses to the heartbeat, the device may augment its analysis.

The present invention provides methods, compositions, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferin or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. Upon addition of the luciferin derivative or other luminogenic molecule into a P450 reaction, the P450 enzyme metabolizes the molecule into a bioluminescent enzyme substrate, e.g., luciferin and / or luciferin derivative metabolite, in a P450 reaction. The resulting metabolite(s) serves as a substrate of the bioluminescent enzyme, e.g., luciferase, in a second light-generating reaction. Luminescent cytochrome P450 assays with low background signals and high sensitivity are disclosed and isoform selectivity is demonstrated. The present invention also provides an improved method for performing luciferase reactions which employs added pyrophosphatase to remove inorganic pyrophosphate, a luciferase inhibitor which may be present in the reaction mixture as a contaminant or may be generated during the reaction. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.

Novel vision monitoring, screening, and testing tools and help-seeking enablers that may be used individually as or in combination with other vision monitoring and screening testing systems that improves patients' ability to recognize the onset and progression of visual changes over time. Patients' ability to identify acute or chronic visual conditions on their own may drive earlier help-seeking behavior by the patient, enable earlier clinical diagnosis by an eye care specialist, and therefore resulting in earlier treatment and reduced likelihood of severe vision loss.

This invention is related to a method for the detection of early or pre-cancer using DNA isolated from blood and body fluids. This invention provides an improved methylation-based PCR assay, a panel of methylated-based cancer-related gene markers for the detection of general cancer and a panel of unmethylation-based tissue- or cell-specific gene markers for discriminating different type of cancer detected from blood samples. This method couples a sequential cancer-related gene marker detection and tissue or cell-specific gene marker assay and is particularly useful as a simultaneous screening test for following type of cancer: lung, breast, ovarian, colon, stomach, prostatic, pancreatic and liver cancer.

A dyslexia screening system suitable for clinical use includes an integrated headset that efficiently and conveniently performs an auditory evoked response (ERP) test by positioning electrodes about the ears of the subject. An integral control module automatically performs the test, providing simplified controls and indications to the clinician. A number of screening tests that are stored in the headset are periodically uploaded for billing, remote analysis and result reporting. A paradigm that characterizes testing performed for a subject along with the patient identification and / or patient demographics are stored in an associated fashion for later fusion and analyses with similar but not necessarily identically constructed ERP tests.